Try
ANAPTYSBIO, INC
ANABUnited States
43 filed reports · 339 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
43 reports · Mar 2017 to Mar 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 9 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 28 | 3,837 | Mar 2017 to Mar 2026 |
| Annual · 10-KSEC EDGAR | 9 | 3,354 | Dec 2017 to Dec 2025 |
| Current · 8-KSEC EDGAR | 5 | 9 | Mar 2020 to Jun 2022 |
| Annual · 10-K/ASEC EDGAR | 1 | 22 | Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 12, 2026 | 376 | Open |
| FY2025 | 10-K/A | Dec 31, 2025 | Apr 28, 2026 | 22 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 3, 2026 | 748 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 235 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 206 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 5, 2025 | 171 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 27, 2025 | 397 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 5, 2024 | 135 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 5, 2024 | 117 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 9, 2024 | 120 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 11, 2024 | 312 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 2, 2023 | 135 | Open |
Financial data
339 concepts · 7,222 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial321 concepts · 6,722 facts · Dec 2015 to May 2026
- Cash cash equivalents restricted cash and restricted cash equivalents52 · Dec 2015 to Mar 2026
- Comprehensive income net of tax52 · Dec 2015 to Mar 2026
- Depreciation depletion and amortization52 · Dec 2015 to Mar 2026
- General and administrative expense (US GAAP)52 · Dec 2015 to Mar 2026
- Increase decrease in accounts payable and accrued liabilities52 · Dec 2015 to Mar 2026
- Increase decrease in prepaid deferred expense and other assets52 · Dec 2015 to Mar 2026
- Net cash provided by used in financing activities52 · Dec 2015 to Mar 2026
- Net cash provided by used in investing activities52 · Dec 2015 to Mar 2026
- Net cash provided by used in operating activities52 · Dec 2015 to Mar 2026
- Net income loss52 · Dec 2015 to Mar 2026
- Nonoperating income expense52 · Dec 2015 to Mar 2026
- Operating expenses (US GAAP)52 · Dec 2015 to Mar 2026
- Operating income loss52 · Dec 2015 to Mar 2026
- Payments to acquire available for sale securities debt52 · Dec 2015 to Mar 2026
- Payments to acquire property plant and equipment52 · Dec 2015 to Mar 2026
- Revenue52 · Dec 2015 to Mar 2026
- Share based compensation arrangement by share based payment award options grants in period gross52 · Dec 2015 to Mar 2026
- Capital expenditures incurred but not yet paid50 · Dec 2015 to Mar 2026
- Other nonoperating income expense50 · Dec 2015 to Mar 2026
- Stockholders equity (US GAAP)50 · Dec 2015 to Mar 2026
- Common stock par or stated value per share49 · Dec 2016 to Mar 2026
- Common stock shares authorized49 · Dec 2016 to Mar 2026
- Preferred stock par or stated value per share49 · Dec 2016 to Mar 2026
- Preferred stock shares authorized49 · Dec 2016 to Mar 2026
Segment14 concepts · 442 facts · Dec 2022 to Mar 2026
- Research and development expense excluding acquired in process cost142 · Dec 2022 to Dec 2025
- General and administrative expense (US GAAP)60 · Dec 2022 to Mar 2026
- ANB03336 · Mar 2025 to Mar 2026
- Income tax expense benefit20 · Dec 2022 to Mar 2026
- Interest income other20 · Dec 2022 to Mar 2026
- Net income loss20 · Dec 2022 to Mar 2026
- Non-cash interest expense for the sale of future royalties20 · Dec 2022 to Mar 2026
- Nonoperating income expense20 · Dec 2022 to Mar 2026
- Operating expenses (US GAAP)20 · Dec 2022 to Mar 2026
- Operating income loss20 · Dec 2022 to Mar 2026
- Other nonoperating income expense20 · Dec 2022 to Mar 2026
- Revenue20 · Dec 2022 to Mar 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest19 · Dec 2022 to Mar 2026
- Research and development asset acquired other than through business combination written off5 · Dec 2022 to Dec 2024
Product3 concepts · 49 facts · Dec 2023 to Mar 2026
- Research and development expense excluding acquired in process cost23 · Dec 2023 to Dec 2025
- ANB03316 · Mar 2025 to Mar 2026
- General and administrative expense (US GAAP)10 · Dec 2023 to Mar 2026
Guidance1 concepts · 9 facts · May 2020 to Aug 2022
- Free Cash Flow Guidance9 · May 2020 to Aug 2022
Segments
491 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments3 members · 442 facts
- Research And Development222 · Dec 2022 to Sep 2025
- Biopharma Company110 · Dec 2023 to Mar 2026
- Royalty Management Company110 · Dec 2023 to Mar 2026
Product or service8 members · 49 facts
- External Expenses10 · Dec 2023 to Mar 2026
- Internal Expenses10 · Dec 2023 to Mar 2026
- ANB0325 · Dec 2023 to Mar 2026
- ANB0335 · Dec 2023 to Mar 2026
- Imsidolimab5 · Dec 2023 to Mar 2026
- Preclinical And Other Unallocated Costs5 · Dec 2023 to Mar 2026
- Rosnilimab5 · Dec 2023 to Mar 2026
- ANB1014 · Dec 2024 to Mar 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.